Are altered pHi and membrane potential in hu MDR 1 transfectants sufficient to cause MDR protein-mediated multidrug resistance?
Open Access
- 1 October 1996
- journal article
- Published by Rockefeller University Press in The Journal of general physiology
- Vol. 108 (4) , 295-313
- https://doi.org/10.1085/jgp.108.4.295
Abstract
Multidrug resistance (MDR) mediated by overexpression of the MDR protein (P-glycoprotein) has been associated with intracellular alkalinization, membrane depolarization, and other cellular alterations. However, virtually all MDR cell lines studied in detail have been created via protocols that involve growth on chemotherapeutic drugs, which can alter cells in many ways. Thus it is not clear which phenotypic alterations are explicitly due to MDR protein overexpression alone. To more precisely define the MDR phenotype mediated by hu MDR 1 protein, we co-transfected hu MDR 1 cDNA and a neomycin resistance marker into LR73 Chinese hamster ovary fibroblasts and selected stable G418 (geneticin) resistant transfectants. Several clones expressing different levels of hu MDR 1 protein were isolated. Unlike previous work with hu MDR 1 transfectants, the clones were not further selected with, or maintained on, chemotherapeutic drugs. These clones were analyzed for chemotherapeutic drug resistance, intracellular pH (pHi), membrane electrical potential (Vm), and stability of MDR 1 protein overexpression. LR73/hu MDR 1 clones exhibit elevated pHi and are depolarized, consistent with previous work with LR73/mu MDR 1 transfectants (Luz, J.G. L.Y. Wei, S. Basu, and P.D. Roepe. 1994. Biochemistry. 33:7239-7249). The extent of these perturbations is related to the level of hu MDR 1 protein that is expressed. Cytotoxicity experiments with untransfected LR73 cells with elevated pHi due to manipulating percent CO2 show that the pHi perturbations in the MDR 1 clones can account for much of the measured drug resistance. Membrane depolarization in the absence of MDR protein expression is also found to confer mild drug resistance, and we find that the pHi and Vm changes can conceivably account for the altered drug accumulation measured for representative clones. These data indicate that the MDR phenotype unequivocally mediated by MDR 1 protein overexpression alone can be fully explained by the perturbations in Vm and pHi that accompany this overexpression. In addition, MDR mediated by MDR protein overexpression alone differs significantly from that observed for MDR cell lines expressing similar levels of MDR protein but also exposed to chemotherapeutic drugs.Keywords
This publication has 62 references indexed in Scilit:
- The role of the MDR protein in altered drug translocation across tumor cell membranesBiochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1995
- Functional Dissection of P-glycoprotein Nucleotide-binding Domains in Chimeric and Mutant ProteinsPublished by Elsevier ,1995
- Kinetics of Transport of Dialkyloxacarbocyanines in Multidrug-Resistant Cell Lines Overexpressing P-glycoprotein: Interrelationship of Dye Alkyl Chain Length, Cellular Flux, and Drug ResistanceBiochemistry, 1995
- Swelling-activated chloride channels in multidrug-sensitive and -resistant cells.The Journal of general physiology, 1994
- Novel Cl--Dependent Intracellular pH Regulation in Murine MDR 1 Transfectants and Potential ImplicationsBiochemistry, 1994
- BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTERAnnual Review of Biochemistry, 1993
- Comparison of adriamycin and derivatives uptake into large unilamellar lipid vesicles in response to a membrane potentialBiochimica et Biophysica Acta (BBA) - Biomembranes, 1993
- Extracellular ATP and cell signallingBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1992
- A model for computer simulation of P-glycoprotein and transmembrane ΔpH-mediated anthracycline transport in multidrug-resistant tumor cellsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1990
- Increased Cytosolic pH in Multidrug-Resistant Human Lung Tumor Cells: Effect of VerapamilJNCI Journal of the National Cancer Institute, 1989